Study sites were selected from hospitals across diverse regions of China. Approximately 6,000 participants who require passive immunization against tetanus due to various injuries (including those with severe wounds or heavily contaminated injuries) will be enrolled per clinical practice: Participants receiving siltartoxatug for tetanus prophylaxis and meeting eligibility criteria will be assigned to the siltartoxatug group (n=4,000); Participants receiving other passive immunizing agents (HTIG, TAT, or F(ab')₂) for tetanus prophylaxis and meeting eligibility criteria will be assigned to the control group (n=2,000), comprising approximately 1,000 HTIG recipients and 1,000 TAT/F(ab')₂ recipients. All clinical management decisions, including concomitant tetanus vaccination, will be made by investigators per standard clinical practice at each center.
Study Type
OBSERVATIONAL
Enrollment
6,000
Dosage form: Injectable solution Strength: 10 mg / 0.5 mL per vial Route and regimen: Single intramuscular injection in the gluteal muscle at a dose of 10 mg
Dosage form, strength, and administration: As specified in the respective product's approved labeling (package insert). All use will follow routine clinical practice per local guidelines.
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
RECRUITINGTetanus protection rate
Tetanus protection rate (1 - tetanus incidence rate) within 90 days post-dosing
Time frame: within 90 days
Tetanus protection rate
Tetanus protection rate (1 - tetanus incidence rate) within 28 days and 130 days post-dosing
Time frame: within 28 days and 130 days
Incidence rates of adverse events (AEs) and serious adverse events (SAEs)
Incidence rates of adverse events (AEs) and serious adverse events (SAEs)
Time frame: within 130 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.